Elan Pharmaceuticals, Inc.

Wyeth

Other

Cortexyme, Inc.

Vivace Therapeutics, Inc.

Cytomx Therapeutics, Inc.

Imago Pharmaceuticals, Inc.

Algen Biotechnologies, Inc.

Concentric Analgesics, Inc.

Amplyx Pharmaceuticals, Inc.

Lighthouse Pharmaceuticals, Inc.

Andrei William Konradi

Anh Truong

Christopher Michael Semko

Michael A Pleiss

Eugene D Thorsett

Ying-Zi Xu

Francine S Grant

Darren B Dressen

Anthony Frank Kreft

Dimitrios Sarantakis

Susan Ashwell

Jenifer Lea Smith

Gregory Scott Welmaker

Frank Stappenbeck

Louis John Lombardo

Casey Crawford Lynch

Stephen S Dominy

Reinhardt Bernhard Baudy

Tracy Tzu-Ling Tang Lin

Joseph P Vacca

Craig Alan Coburn

Simeon Bowers

Michael S Dappen

Anh P Truong

Kassandra Inez Rossiter

Roy K Hom

Juri Y Fukuda

Albert W Garofalo

Gary D Probst

Brian P Stupi

Robert A Galemmo, Jr

Hing L Sham

Theodore A Yednock

Christopher Joseph Soares

R Jeffrey Neitz

Jennifer Sealy

Francine S Farouz

Gergely Toth

Luc Roland Desnoyers

Henry Bernard Lowman

Jing Wu

Kiev S Ly

Christine M Tarby

Stephen B Freedman

Martin Neitzel

Tony Liang

Shweta Singh

Matthew N Mattson

Xiaocong Michael Ye

Leslie Jean Holsinger

Elizabeth Messersmith

Robert Warren Sullivan

Chun-Hao Huang

Ko-Chuan Lee

Craig Husfeld

Shendong Yuan

Minghua Sun

Danielle Aubele

Ivan Lieberburg

Ted A Yednock

Jonathan A Covel

Jacek J Jagodzinski

Raymond Ng

Michael Grey

David Wone

Leslie J Holsinger

Casey C Lynch

Chris Semko

Jacek J Jagodinski

George Shopp

Chris Vandevert

Stephen J Karlik

Michael A Pliess

Brian P Stupl

Dimitrios Sarntakis

The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.

Certain chemical compositions and methods of use thereof

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated withinfection, including brain disorders such as Alzheimer's disease.

Ketone inhibitors of lysine gingipain

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Bicyclic compounds

The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.

Compositions and methods for conjugating activatable antibodies

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

Pyridine derivatives substituted by heterocyclic ring and amino group

Oxadiazole compounds

Benzocarbonyl compounds

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

The present invention relates generally to therapeutics targeting the bacterium, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated withinfection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof. 

Inhibitors of lysine gingipain

Benzosulfonyl compounds

Non-fused tricyclic compounds

The present invention relates generally to therapeutics targeting the bacterium, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated withinfection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

Aminopyridine compounds and methods for the preparation and use thereof

Growing community of inventors

Burlingame, CA, United States of America

Andrei William Konradi